{"id":20457,"date":"2024-05-16T04:30:00","date_gmt":"2024-05-16T08:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-annonce-les-resultats-de-son-assemblee-generale-mixte-2024\/"},"modified":"2024-05-16T04:30:00","modified_gmt":"2024-05-16T08:30:00","slug":"dbv-technologies-annonce-les-resultats-de-son-assemblee-generale-mixte-2024","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-annonce-les-resultats-de-son-assemblee-generale-mixte-2024\/","title":{"rendered":"DBV Technologies annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Mixte 2024"},"content":{"rendered":"<div class=\"pr-date-globe\">May 16, 2024 16:30 ET<\/div>\n<p align=\"right\">Ch\u00e2tillon, France, le 16 mai 2024<\/p>\n<p align=\"justify\"><strong>DBV Technologies annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale Mixte 2024 <\/strong><\/p>\n<p align=\"justify\"><strong>Toutes les r\u00e9solutions propos\u00e9es \u00e0 l\u2019Assembl\u00e9e G\u00e9n\u00e9rale ont \u00e9t\u00e9 adopt\u00e9es<\/strong><\/p>\n<p align=\"justify\">DBV Technologies &lpar;Euronext&nbsp;: DBV \u2013 ISIN&nbsp;: FR0010417345 \u2013 Nasdaq Stock Market&nbsp;: DBVT), &lpar;la \u00ab <strong>Soci\u00e9t\u00e9<\/strong> \u00bb), une&nbsp;entreprise biopharmaceutique de stade clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits, a tenu son Assembl\u00e9e G\u00e9n\u00e9rale Mixte &lpar;l\u2019\u00ab&nbsp;<strong>Assembl\u00e9e G\u00e9n\u00e9rale<\/strong>&nbsp;\u00bb). L\u2019Assembl\u00e9e G\u00e9n\u00e9rale s\u2019est d\u00e9roul\u00e9e au si\u00e8ge social de la Soci\u00e9t\u00e9, sous la pr\u00e9sidence de Michel de Rosen, Pr\u00e9sident du Conseil d\u2019administration de la Soci\u00e9t\u00e9. <\/p>\n<p align=\"justify\">Toutes les r\u00e9solutions pr\u00e9sent\u00e9es par le Conseil d\u2019administration ont \u00e9t\u00e9 adopt\u00e9es. Ces r\u00e9solutions et leurs r\u00e9sultats sont accessibles sur le site internet de la Soci\u00e9t\u00e9, dans la rubrique Investisseurs\/Assembl\u00e9es g\u00e9n\u00e9rales annuelles <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7OHRT1XjPK4Rcy4b4tJtUTnHh_cqz4Pym3r8n6FoYgxY_7lYReQQy6Dw-pwbqFrhTABbSVBnMvI40EPLD9EsYKpFppsriqBf9wCA3fzwi84LPL1UFk2vFDH_PM3l7j6j6r7vRLMjffGaEmx0HRJd2oNzCMrjDjqVwoMkqcMMmjC1DLTVtszs6MY2gNq-hk4IFBOWS4BfXqfyQVW9hqaOsA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/dbv-technologies.com\/events\/2024-annual-general-meeting\/<\/a>.<\/p>\n<p align=\"left\"><strong>\u00c0 propos de DBV&nbsp;Technologies<\/strong><br \/>DBV Technologies est une entreprise biopharmaceutique de stade clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits. DBV se concentre actuellement sur l&rsquo;\u00e9tude de l&rsquo;utilisation de sa plateforme technologique exclusive, Viaskin\u2122, pour traiter les allergies alimentaires caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une gamme de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l&rsquo;anaphylaxie potentiellement mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l&rsquo;immunoth\u00e9rapie \u00e9picutan\u00e9e &lpar;EPIT\u2122), la plateforme Viaskin est con\u00e7ue pour dispenser des quantit\u00e9s de microgrammes d&rsquo;un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L&rsquo;EPIT est une nouvelle classe de traitement non invasif cherchant \u00e0 modifier l&rsquo;allergie sous-jacente d&rsquo;un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire \u00e0 se d\u00e9sensibiliser \u00e0 l&rsquo;allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s&rsquo;est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d&rsquo;allergies alimentaires. Les programmes d&rsquo;allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des \u00e9tudes cliniques en cours avec Viaskin Peanut chez les jeunes enfants &lpar;de 1 \u00e0 3 ans) et les enfants &lpar;de 4 \u00e0 7 ans) allergiques \u00e0 l&rsquo;arachide.<\/p>\n<p align=\"justify\">Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Ch\u00e2tillon, en France, avec des op\u00e9rations nord-am\u00e9ricaines bas\u00e9es \u00e0 Warren dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris &lpar;symbole&nbsp;: DBV, code ISIN&nbsp;: FR0010417345) et les ADS de la Soci\u00e9t\u00e9 &lpar;chacun repr\u00e9sentant une demi-action ordinaire) sont n\u00e9goci\u00e9s sur le Nasdaq Global Select Market &lpar;symbole&nbsp;: DBVT)<\/p>\n<p align=\"justify\">Pour plus d\u2019informations, veuillez consulter <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Nl7JK-HSVJXGc5qHa2sMP-fOL5ltkMr1qMQThKRiajxAOWD6qmhBz9safKq3KBKtrT9U3JYQyFq0UbbHw9USkPAavuKvjGll5c0WkV6bbiZD5NHITXOwxwgcVMz6BIB\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.dbv-technologies.com\">www.dbv-technologies.com<\/a> et nous contacter sur <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l2Uft9rSOx96c4PELGKvhozE20lLXoAJr1OpZxi7E9HfnrfzH5AKYgx6y39LOcUgCKiYsZhcEBFaWjrWJFbMiSb4B4JOO8jZp19aQMhTxC5o1gHgustX1RRf6sGvJlwS\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>X &lpar;anciennement Twitter)<\/u><\/a> et <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ORsOSHvfDbT7Uruv5dj7u-vSzzwnBOB1vCulmsBICgypLET-1b_2CKrqCOCMUfriMi1sn4vwWaoJVu36Aoml19AUsJQYzQeX7TO4Swq4fvt7Jv4kN0tmDOcoKRkilvpE\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a>. <\/p>\n<p align=\"justify\">Viaskin et EPIT sont des marques commerciales de DBV Technologies.<\/p>\n<p align=\"justify\"><strong>Contact avec les investisseurs <\/strong><br \/>Katie Matthews<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XRrBU0amnVvHdAVaRDVNjftySuq9fMjh4KXRHEy4u-gYsqG4k1btLxtGzLFT4UG2SRr90_3hdfc0I7vyoEnL7ok9yCYTBzx8m80K5CQLr56F-Zh95G9TU_t3TGVn-xPw4K4FNiG_BzFdB91VTmOTDg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>katie.matthews@dbv-technologies.com<\/u><\/a><\/p>\n<p align=\"justify\"><strong>Contact avec les m\u00e9dias<\/strong><br \/>Aurora Krause<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xtTw3GH0wvDt1Iyo7QB2IcDnDLBWRy9Wul8EInGpOz0QwVF5iTg6jBhPjmdnTWvjJvL_NiMqRPOiEHQnOFkrH824H4xMqm6alBM4oPtermnIZp2Sad1Q69DQlm3M4wEW5gqzw4xnjCEsskVHrOdNnQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>aurora.krause-ext@dbv-technologies.com<\/u><\/a><\/p>\n<\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=uqr9xGbweVUGF4jL5MgF_H9vcrojT01kvp0-O3oi1KLqpR1tOSiyTtBY4gbg1wVP_7breb4urjc1zKFxmS1FrNEz82uNqL14ITALOjQ7E4Q5QeGEFq_NSLRPwRLNqwl7TLj5JZgnZGq1Fflh9ADOEBAtbT38qMxkwTTIvh3F7wM=\" title=\"version PDF\" rel=\"nofollow noopener\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/NTFjYTIzNTYtMTM1Mi00OWQ2LWE4ZDAtOWE5Y2M0MjgxNzkxLTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">            <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-20457","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/20457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/20457\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=20457"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=20457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}